HEADER HYDROLASE 02-AUG-21 7ROV TITLE KRAS G12D MUTANT IN COMPLEX WITH GMPPCP AND CYCLIC PEPTIDE MP-9903 COMPND MOL_ID: 1; COMPND 2 MOLECULE: ISOFORM 2B OF GTPASE KRAS; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: K-RAS 2,KI-RAS,C-K-RAS,C-KI-RAS; COMPND 5 EC: 3.6.5.2; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIC PEPTIDE MP-9903; COMPND 10 CHAIN: E, F; COMPND 11 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: KRAS, KRAS2, RASK2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 MOL_ID: 2; SOURCE 9 SYNTHETIC: YES; SOURCE 10 ORGANISM_SCIENTIFIC: SYNTHETIC CONSTRUCT; SOURCE 11 ORGANISM_TAXID: 32630 KEYWDS KRAS, CYCLIC PEPTIDE, NON-NATURAL AMINO ACID, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR P.ORTH REVDAT 4 15-NOV-23 7ROV 1 LINK ATOM REVDAT 3 18-OCT-23 7ROV 1 JRNL REVDAT 2 26-JAN-22 7ROV 1 JRNL REVDAT 1 22-SEP-21 7ROV 0 JRNL AUTH S.LIM,N.BOYER,N.BOO,C.HUANG,G.VENKATACHALAM, JRNL AUTH 2 Y.C.ANGELA JUANG,M.GARRIGOU,H.Y.K.KAAN,R.DUGGAL,K.M.PEH, JRNL AUTH 3 A.SADRUDDIN,P.GOPAL,T.Y.YUEN,S.NG,S.KANNAN,C.J.BROWN, JRNL AUTH 4 C.S.VERMA,P.ORTH,A.PEIER,L.GE,X.YU,B.BHATT,F.CHEN,E.WANG, JRNL AUTH 5 N.J.LI,R.J.GONZALES,A.STOECK,B.HENRY,T.K.SAWYER,D.P.LANE, JRNL AUTH 6 C.W.JOHANNES,K.BISWAS,A.W.PARTRIDGE JRNL TITL DISCOVERY OF CELL ACTIVE MACROCYCLIC PEPTIDES WITH ON-TARGET JRNL TITL 2 INHIBITION OF KRAS SIGNALING. JRNL REF CHEM SCI V. 12 15975 2021 JRNL REFN ISSN 2041-6520 JRNL PMID 35024121 JRNL DOI 10.1039/D1SC05187C REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH S.LIM,N.BOYER,N.BOO,C.HUANG,G.VENKATACHALAM,Y.C.A.JUANG, REMARK 1 AUTH 2 M.GARRIGOU,K.KAAN,K.M.PEH,A.SADRUDDIN,P.GOPAL,R.DUGGAL, REMARK 1 AUTH 3 T.Y.YUEN,S.NG,S.KANNAN,C.J.BROWN,C.VERMA,P.ORTH,A.PEIER, REMARK 1 AUTH 4 L.GE,X.YU,B.BHATT,F.CHEN,E.WANG,N.J.LI,R.GONZALEZ,A.STOECK, REMARK 1 AUTH 5 B.HENRY,T.K.SAWYER,D.P.LANE,C.W.JOHANNES,K.BISWAS, REMARK 1 AUTH 6 A.W.PARTRIDGE REMARK 1 TITL DISCOVERY OF CELL ACTIVE MACROCYCLIC PEPTIDES WITH ON-TARGET REMARK 1 TITL 2 INHIBITION OF KRAS SIGNALING REMARK 1 REF BIORXIV 2021 REMARK 1 REFN ISSN 2692-8205 REMARK 1 DOI 10.1101/2021.09.11.459913 REMARK 2 REMARK 2 RESOLUTION. 1.32 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.8 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.32 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 47.94 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 90.1 REMARK 3 NUMBER OF REFLECTIONS : 74611 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.195 REMARK 3 R VALUE (WORKING SET) : 0.194 REMARK 3 FREE R VALUE : 0.216 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 3606 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.32 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.33 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 54.02 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : NULL REMARK 3 BIN R VALUE (WORKING + TEST SET) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2818 REMARK 3 BIN FREE R VALUE : 0.3083 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 61 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2863 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 72 REMARK 3 SOLVENT ATOMS : 307 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 19.76 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.00390 REMARK 3 B22 (A**2) : -0.14830 REMARK 3 B33 (A**2) : 0.15220 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.02990 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.180 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.062 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.062 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.061 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.061 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.954 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.950 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 3000 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 4075 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1064 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 507 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 3000 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 401 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2824 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.00 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.84 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 18.40 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7ROV COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 03-AUG-21. REMARK 100 THE DEPOSITION ID IS D_1000258689. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-MAR-18 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : AUTOPROC REMARK 200 DATA SCALING SOFTWARE : STARANISO REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 74611 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.320 REMARK 200 RESOLUTION RANGE LOW (A) : 47.900 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.2 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 9.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.32 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.36 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 5XCO REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 36.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.93 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100MM BIS-TRIS AND 25% PEG 4000, PH REMARK 280 6.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 35.88200 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2110 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8710 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -21.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2350 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8190 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -24.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 REMARK 400 THE CYCLIC PEPTIDE MP-9903 IS OLIGOPEPTIDE, A MEMBER OF SUBSTRATE REMARK 400 ANALOG CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: CYCLIC PEPTIDE MP-9903 REMARK 400 CHAIN: E, F REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLU A 168 REMARK 465 LYS A 169 REMARK 465 MET A 170 REMARK 465 SER A 171 REMARK 465 LYS A 172 REMARK 465 ASP A 173 REMARK 465 GLY A 174 REMARK 465 LYS A 175 REMARK 465 LYS A 176 REMARK 465 LYS A 177 REMARK 465 LYS A 178 REMARK 465 LYS A 179 REMARK 465 LYS A 180 REMARK 465 SER A 181 REMARK 465 LYS A 182 REMARK 465 THR A 183 REMARK 465 LYS A 184 REMARK 465 CYS A 185 REMARK 465 VAL A 186 REMARK 465 ILE A 187 REMARK 465 MET A 188 REMARK 465 GLU B 168 REMARK 465 LYS B 169 REMARK 465 MET B 170 REMARK 465 SER B 171 REMARK 465 LYS B 172 REMARK 465 ASP B 173 REMARK 465 GLY B 174 REMARK 465 LYS B 175 REMARK 465 LYS B 176 REMARK 465 LYS B 177 REMARK 465 LYS B 178 REMARK 465 LYS B 179 REMARK 465 LYS B 180 REMARK 465 SER B 181 REMARK 465 LYS B 182 REMARK 465 THR B 183 REMARK 465 LYS B 184 REMARK 465 CYS B 185 REMARK 465 VAL B 186 REMARK 465 ILE B 187 REMARK 465 MET B 188 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 31 CG CD OE1 OE2 REMARK 470 LYS A 167 CG CD CE NZ REMARK 470 ASP B 38 CG OD1 OD2 REMARK 470 GLU B 62 CG CD OE1 OE2 REMARK 470 GLU B 63 CG CD OE1 OE2 REMARK 470 ARG B 73 CG CD NE CZ NH1 NH2 REMARK 470 LYS B 128 CG CD CE NZ REMARK 470 ALA E 14 CA C O CB REMARK 470 ALA F 14 CA C O CB REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 117 31.08 71.73 REMARK 500 SER A 122 49.35 -79.17 REMARK 500 GLN B 61 1.90 -61.26 REMARK 500 LYS B 117 31.47 70.07 REMARK 500 SER B 122 47.81 -82.64 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MG A2002 MG REMARK 620 N RES CSSEQI ATOM REMARK 620 1 SER A 17 OG REMARK 620 2 GCP A2001 O1G 173.9 REMARK 620 3 GCP A2001 O2B 91.6 92.5 REMARK 620 4 HOH A2114 O 85.4 90.1 90.2 REMARK 620 5 HOH A2130 O 88.4 96.1 89.5 173.8 REMARK 620 6 HOH A2180 O 84.6 91.5 175.5 91.8 88.1 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MG B2003 MG REMARK 620 N RES CSSEQI ATOM REMARK 620 1 SER B 17 OG REMARK 620 2 GCP B2001 O2G 173.5 REMARK 620 3 GCP B2001 O2B 89.8 91.7 REMARK 620 4 HOH B2115 O 84.1 89.5 93.6 REMARK 620 5 HOH B2132 O 89.2 97.1 89.3 172.7 REMARK 620 6 HOH B2171 O 89.2 89.9 174.7 91.5 85.4 REMARK 620 N 1 2 3 4 5 DBREF 7ROV A 1 188 UNP P01116 RASK_HUMAN 1 188 DBREF 7ROV B 1 188 UNP P01116 RASK_HUMAN 1 188 DBREF 7ROV E 1 14 PDB 7ROV 7ROV 1 14 DBREF 7ROV F 1 14 PDB 7ROV 7ROV 1 14 SEQADV 7ROV ALA A 0 UNP P01116 EXPRESSION TAG SEQADV 7ROV ASP A 12 UNP P01116 GLY 12 ENGINEERED MUTATION SEQADV 7ROV ALA B 0 UNP P01116 EXPRESSION TAG SEQADV 7ROV ASP B 12 UNP P01116 GLY 12 ENGINEERED MUTATION SEQRES 1 A 189 ALA MET THR GLU TYR LYS LEU VAL VAL VAL GLY ALA ASP SEQRES 2 A 189 GLY VAL GLY LYS SER ALA LEU THR ILE GLN LEU ILE GLN SEQRES 3 A 189 ASN HIS PHE VAL ASP GLU TYR ASP PRO THR ILE GLU ASP SEQRES 4 A 189 SER TYR ARG LYS GLN VAL VAL ILE ASP GLY GLU THR CYS SEQRES 5 A 189 LEU LEU ASP ILE LEU ASP THR ALA GLY GLN GLU GLU TYR SEQRES 6 A 189 SER ALA MET ARG ASP GLN TYR MET ARG THR GLY GLU GLY SEQRES 7 A 189 PHE LEU CYS VAL PHE ALA ILE ASN ASN THR LYS SER PHE SEQRES 8 A 189 GLU ASP ILE HIS HIS TYR ARG GLU GLN ILE LYS ARG VAL SEQRES 9 A 189 LYS ASP SER GLU ASP VAL PRO MET VAL LEU VAL GLY ASN SEQRES 10 A 189 LYS CYS ASP LEU PRO SER ARG THR VAL ASP THR LYS GLN SEQRES 11 A 189 ALA GLN ASP LEU ALA ARG SER TYR GLY ILE PRO PHE ILE SEQRES 12 A 189 GLU THR SER ALA LYS THR ARG GLN GLY VAL ASP ASP ALA SEQRES 13 A 189 PHE TYR THR LEU VAL ARG GLU ILE ARG LYS HIS LYS GLU SEQRES 14 A 189 LYS MET SER LYS ASP GLY LYS LYS LYS LYS LYS LYS SER SEQRES 15 A 189 LYS THR LYS CYS VAL ILE MET SEQRES 1 B 189 ALA MET THR GLU TYR LYS LEU VAL VAL VAL GLY ALA ASP SEQRES 2 B 189 GLY VAL GLY LYS SER ALA LEU THR ILE GLN LEU ILE GLN SEQRES 3 B 189 ASN HIS PHE VAL ASP GLU TYR ASP PRO THR ILE GLU ASP SEQRES 4 B 189 SER TYR ARG LYS GLN VAL VAL ILE ASP GLY GLU THR CYS SEQRES 5 B 189 LEU LEU ASP ILE LEU ASP THR ALA GLY GLN GLU GLU TYR SEQRES 6 B 189 SER ALA MET ARG ASP GLN TYR MET ARG THR GLY GLU GLY SEQRES 7 B 189 PHE LEU CYS VAL PHE ALA ILE ASN ASN THR LYS SER PHE SEQRES 8 B 189 GLU ASP ILE HIS HIS TYR ARG GLU GLN ILE LYS ARG VAL SEQRES 9 B 189 LYS ASP SER GLU ASP VAL PRO MET VAL LEU VAL GLY ASN SEQRES 10 B 189 LYS CYS ASP LEU PRO SER ARG THR VAL ASP THR LYS GLN SEQRES 11 B 189 ALA GLN ASP LEU ALA ARG SER TYR GLY ILE PRO PHE ILE SEQRES 12 B 189 GLU THR SER ALA LYS THR ARG GLN GLY VAL ASP ASP ALA SEQRES 13 B 189 PHE TYR THR LEU VAL ARG GLU ILE ARG LYS HIS LYS GLU SEQRES 14 B 189 LYS MET SER LYS ASP GLY LYS LYS LYS LYS LYS LYS SER SEQRES 15 B 189 LYS THR LYS CYS VAL ILE MET SEQRES 1 E 14 ALA 060 PRO LEU TYR ILE SER TYR ASP PRO VAL CYS ARG SEQRES 2 E 14 ALA SEQRES 1 F 14 ALA 060 PRO LEU TYR ILE SER TYR ASP PRO VAL CYS ARG SEQRES 2 F 14 ALA HET 060 E 2 7 HET 060 F 2 7 HET GCP A2001 32 HET MG A2002 1 HET GCP B2001 32 HET GOL B2002 6 HET MG B2003 1 HETNAM 060 S-METHYL-D-CYSTEINE HETNAM GCP PHOSPHOMETHYLPHOSPHONIC ACID GUANYLATE ESTER HETNAM MG MAGNESIUM ION HETNAM GOL GLYCEROL HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 3 060 2(C4 H9 N O2 S) FORMUL 5 GCP 2(C11 H18 N5 O13 P3) FORMUL 6 MG 2(MG 2+) FORMUL 8 GOL C3 H8 O3 FORMUL 10 HOH *307(H2 O) HELIX 1 AA1 GLY A 15 ASN A 26 1 12 HELIX 2 AA2 SER A 65 GLY A 75 1 11 HELIX 3 AA3 ASN A 86 ASP A 92 1 7 HELIX 4 AA4 ASP A 92 ASP A 105 1 14 HELIX 5 AA5 ASP A 126 GLY A 138 1 13 HELIX 6 AA6 GLY A 151 LYS A 165 1 15 HELIX 7 AA7 GLY B 15 ASN B 26 1 12 HELIX 8 AA8 SER B 65 GLY B 75 1 11 HELIX 9 AA9 ASN B 86 ASP B 92 1 7 HELIX 10 AB1 ASP B 92 ASP B 105 1 14 HELIX 11 AB2 ASP B 126 GLY B 138 1 13 HELIX 12 AB3 GLY B 151 LYS B 167 1 17 SHEET 1 AA1 6 ASP A 38 ILE A 46 0 SHEET 2 AA1 6 GLU A 49 ASP A 57 -1 O CYS A 51 N VAL A 44 SHEET 3 AA1 6 THR A 2 GLY A 10 1 N VAL A 8 O LEU A 56 SHEET 4 AA1 6 GLY A 77 ALA A 83 1 O VAL A 81 N VAL A 9 SHEET 5 AA1 6 MET A 111 ASN A 116 1 O ASN A 116 N PHE A 82 SHEET 6 AA1 6 PHE A 141 GLU A 143 1 O ILE A 142 N LEU A 113 SHEET 1 AA2 6 ASP B 38 ILE B 46 0 SHEET 2 AA2 6 GLU B 49 ASP B 57 -1 O ILE B 55 N TYR B 40 SHEET 3 AA2 6 GLU B 3 GLY B 10 1 N TYR B 4 O LEU B 52 SHEET 4 AA2 6 GLY B 77 ALA B 83 1 O VAL B 81 N VAL B 9 SHEET 5 AA2 6 MET B 111 ASN B 116 1 O ASN B 116 N PHE B 82 SHEET 6 AA2 6 PHE B 141 GLU B 143 1 O ILE B 142 N LEU B 113 LINK C ALA E 1 N 060 E 2 1555 1555 1.33 LINK C 060 E 2 N PRO E 3 1555 1555 1.35 LINK CS 060 E 2 SG CYS E 12 1555 1555 1.80 LINK C ALA F 1 N 060 F 2 1555 1555 1.33 LINK C 060 F 2 N PRO F 3 1555 1555 1.35 LINK CS 060 F 2 SG CYS F 12 1555 1555 1.77 LINK OG SER A 17 MG MG A2002 1555 1555 2.11 LINK O1G GCP A2001 MG MG A2002 1555 1555 2.09 LINK O2B GCP A2001 MG MG A2002 1555 1555 2.01 LINK MG MG A2002 O HOH A2114 1555 1555 2.10 LINK MG MG A2002 O HOH A2130 1555 1555 2.14 LINK MG MG A2002 O HOH A2180 1555 1555 2.05 LINK OG SER B 17 MG MG B2003 1555 1555 2.14 LINK O2G GCP B2001 MG MG B2003 1555 1555 2.09 LINK O2B GCP B2001 MG MG B2003 1555 1555 2.07 LINK MG MG B2003 O HOH B2115 1555 1555 2.06 LINK MG MG B2003 O HOH B2132 1555 1555 2.18 LINK MG MG B2003 O HOH B2171 1555 1555 2.13 CRYST1 38.793 71.764 65.481 90.00 100.29 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.025778 0.000000 0.004680 0.00000 SCALE2 0.000000 0.013935 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015521 0.00000